Legal Status Indication Treatment of Type 1 and Type 2 diabetes
|
|
- Maria Caldwell
- 5 years ago
- Views:
Transcription
1 New Medicine Report (Adopted by the CCG until review and further notice) Document Status Recombinant human insulin analogues Following Suffolk D&TC Meeting Traffic Light Decision Green Date of Last Revision 11 th July 2005 Approved Name Various Trade Name Various Manufacturer Various Legal Status POM Indication Treatment of Type 1 and Type 2 diabetes Dosage As required Cost See document Possible Number of Suffolk See document Patients Number Needed to Treat Not calculated Treatment Alternatives See document Future Alternatives Insulin glulisine short acting insulin analogue Possible Future Indications None known Submitted for comment to: Dr G Rayman, The Ipswich Hospital Dr Parkinson, The Ipswich Hospital Dr Fowler, The Ipswich Hospital Dr T Lockington, The Ipswich Hospital Dr N Wijenaike, West Suffolk Hospital Dr J Clark, West Suffolk Hospital Dr J Majeed, West Suffolk Hospital Dr N Huston, James Paget Date Not to be used for promotional purposes Page 1 of 13 May be freely copied by NHS agencies
2 The following paper has been adapted to reflect the Suffolk population but was originally prepared for:- CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Recombinant human insulin analogues aspart, detemir, glargine, lispro Treatment of type 1 & type 2 diabetes mellitus Date of last revision 1 April 2005, version 1 Prepared by Katie Smith, Medicines Review & Primary Care Support Pharmacist, East Anglia Medicines Information Service and Sue Ashwell, Cambridge Joint Prescribing Group pharmacist Purpose of document To review information currently available Points For Consideration There is a need to establish the analogues long term benefits & safety. There is no convincing evidence to justify switching patients from existing conventional therapy to analogues if they have appropriate glycaemic control and no troublesome hypoglycaemia. The insulin analogues provide useful options for patients with type 1 diabetes predominantly who have frequent severe hypoglycaemia or nocturnal hypoglycaemic episodes. Treatment Alternatives Type 1 diabetics metformin may have a role in patients who are overweight or require large doses of insulin Place in current therapy Type 2 diabetics diet control, weight loss, oral antidiabetic drugs Type 1 diabetics analogues used increasingly as first line therapy Type 2 diabetics -? Future Alternatives Insulin glulisine - short acting insulin analogue like aspart & lispro Review date NICE issued guidance on management of blood glucose in type 2 diabetics in September 2002, due to be reviewed September 2005 NICE issued guidance on use of insulin glargine in December 2002, due to be reviewed in November 2005 NICE issued guidance on use of insulin pump therapy in February 2003, due to be reviewed in February 2006 NICE issued guidance on management on type 1 diabetics in July 2004, due to be reviewed July 2008 Indication For the treatment of patients with diabetes mellitus Cautions [For more detail, refer to the NovoRapid, Levemir, Lantus, Humalog, NovoMix 30 & Humalog Mix25 Summaries of Product Characteristics on the Electronic Medicines Compendium (EMC) - Hypoglycaemia Hyperglycaemia Diabetic ketoacidosis Concomitant illness Children younger than 6 years old Pregnant women aspart & lispro ok, detemir?, glargine not ok Not to be used for promotional purposes Page 2 of 13 May be freely copied by NHS agencies
3 [For further detailed information refer to the NovoRapid, Levemir, Lantus, Humalog, NovoMix 30 & Humalog Mix25 Summaries of Product Characteristics on the EMC] Source of Review Humalog a new insulin analogue, DTB Aug 1997 Vol 35 (8) p57-8 Short acting insulin analogues vs regular human insulin in patients with diabetes mellitus. Cochrane Database of Systematic Reviews 2004, issue 4 Insulin detemir (Levemir) a new basal insulin analogue, London New Drugs Group APC/DTC Briefing August 2004 BNF 48 th Ed Sept 2004 p Update on insulin analogues, DTB Oct 2004 Vol 42 (10) p77-80 Insulin analogues, NEJM 13 Jan 2005 Vol 352 (2) p Current insulin therapies for people with type 1 diabetes, Prescriber 19 March 2005 Vol 16 (6) p48-65 Guidance on use The recombinant human analogues have been developed to closely match the amino acid structure of human insulin and also more closely duplicate insulin requirements. Before the introduction of insulin analogues, all diabetic patients requiring insulin were treated with a twice daily split mix regimen of NPH insulin (intermediate acting) and regular soluble human insulin (short acting). The split mix aims to cover the physiological insulin release although this is difficult to achieve in practice. Insulin replacement consists of prandial insulin and basal insulin. Prandial insulin is given in an attempt to mimic the response of endogenous insulin to food. The basal insulin component mimics the relatively small but constant release of insulin that regulates lipolysis and output of hepatic glucose. The split mix insulin regimen spans both the prandial and basal components whereas insulin analogues target prandial and basal components separately. When injected subcutaneously, soluble insulin has an onset of action within minutes, a peak action between 2 and 4 hours and a duration of action of up to 8 hours. Although termed short acting, problems have arisen because the increase in insulin level is slower and more prolonged compared to normal physiological insulin release. The speed of absorption is determined by how quickly the chain of amino acids breaks down to single molecule units, which can be rapidly absorbed. Endogenous insulin peaks about 1 hour after release and lasts for about 4 hours. NPH insulin accounts for over 80% of the insulin currently prescribed for basal therapy in the UK. NPH insulin however has a time course of action that may result in nocturnal hypoglycaemia. It peaks 3-5 hours after injection and its duration of action is 14 +/- 3 hours so it may need to be injected twice daily. The ideal basal insulin has a long duration of action, typically 24 hours with minimal variability in absorption & once daily administration. Not to be used for promotional purposes Page 3 of 13 May be freely copied by NHS agencies
4 Insulin aspart & insulin lispro are rapid acting analogues that are derivatives of human insulin. Their onset of action occurs in minutes, the peak action follows within hours and the duration of action is 3-5 hours. When the DTB reviewed insulin lispro in August 1997 they concluded that Following subcutaneous injection, it has a more rapid onset, time to peak and shorter duration of action than soluble human insulin. It can be given immediately before a meal. It does not appear to alter overall control (haemoglobin A1c levels) It is not clear whether it reduces the occurrence of hypoglycaemia compared with soluble human insulin. At present there is no indication for replacing soluble human insulin with insulin lispro in the majority of patients. It may help patients whose mealtimes are unpredictable, those who eat late in the evening and are prone to early nocturnal hypoglycaemia. A 2004 Cochrane review compared the data on short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. The systematic review of 42 randomised controlled trials concluded that - 7 trials compared insulin aspart, 34 trials compared insulin lispro and 1 trial compared both aspart & lispro with conventional human insulin. Trials lasted 1-12 months (mean 3.6 months). Patients included in the trials had type 1 (5,925), type 2 (1,901) or gestational (107) diabetes. The reviewers concluded that 83% of the studies were of poor methodological quality because of randomisation and allocation method issues. Compared with conventional human insulin, use of the analogues was associated with a small decrease in HbA1c levels in type 1 diabetics but not type 2 diabetics. Use of an analogue did not reduce the overall frequency of hypoglycaemia compared with human insulin in either type 1 or type 2 diabetics. Severe hypoglycaemia occurred less often with the analogues than with human insulin (see below) Insulin analogues Type 1: 20.3 episodes/100 person years years Type 2: 0.6 episodes/100 person years years Human insulin 37.2 episodes/100 person 2.8 episodes/100 person None of the studies were designed to assess the possible long term benefits or safety of the short acting insulin analogues. Both insulin aspart and insulin lispro are also available as pre-mixed Not to be used for promotional purposes Page 4 of 13 May be freely copied by NHS agencies
5 formulations NovoMix and Humalog Mix. A percentage of the analogue (30-75%) is co-crystallised with protamine so that the absorption of insulin is slowed to a rate similar to that of an intermediate acting conventional insulin. Data from 9 randomised controlled trials involving 1,347 patients with type 1 or type 2 diabetes suggest that biphasic insulin aspart and biphasic insulin lispro have similar effects on HbA1c and incidence of hypoglycaemia as biphasic conventional insulin but reduce postprandial glucose concentrations more. Summary Compared to soluble human insulin, aspart & lispro result in a small decrease in HbA1c levels in type 1 but not type 2 diabetics. Aspart & lispro reduce the incidence of severe hypoglycaemia but not the overall likelihood of hypoglycaemia. Insulin detemir & insulin glargine are long acting insulins. There have not been any head to head comparisons of the safety and efficacy of the 2 analogues. Current information on insulin detemir was reviewed in the DTB in October 2004 and the London New Drugs Group in August The conclusions are that - Insulin detemir has a novel pharmacological profile in that the insulin molecule reversibly binds to albumin thus delaying its action and resulting in a prolonged duration of action up to 24 hours. It can be administered once or twice daily depending on the patients needs in combination with meal related short or rapid acting insulin. There is limited published information on insulin detemir. In clinical trials it has been compared to NPH insulin. In clinical trials there was no difference in HbA1c levels with insulin detemir and NPH insulin. Insulin detemir appears to provide more stable glycaemic control with less risk of nocturnal hypoglycaemia. Although in one study the total number of hypoglycaemic episodes was similar to NPH insulin and some of the episodes were more serious. Patients using NPH insulin gained on average 0.6kg more weight than those on insulin detemir. 2 small studies have compared patients using soluble human insulin + NPH insulin with patients using insulin detemir + insulin aspart. An 18 week study of 595 type 1 diabetics showed that the patients using the detemir + aspart combination had lower mean HbA1c levels than those using the soluble + NPH combination (7.88% vs. 8.11%, p<0.001) and also had a lower risk of overall and nocturnal hypoglycaemia. Those on insulin detemir had a 1kg lower final body weight (p<0.001). A 22 week study of 395 type 2 diabetics showed that patients using the 2 regimens had similar HbA1c levels and similar numbers of nocturnal hypoglycaemic episodes. The patients on insulin detemir experienced less weight gain (0.51kg vs. 1.13kg, p=0.038). Insulin detemir may offer an advantage over insulin glargine in that it Not to be used for promotional purposes Page 5 of 13 May be freely copied by NHS agencies
6 can be administered using the already widely used Novopen 3 device whereas insulin glargine has to be administered via the less familiar Optipen or Autopen devices. For patients requiring high doses of basal insulin, up to 70 units can be delivered with the single injection with the Novopen however with the Optipen and Autopen devices, the single maximum doses are 60 units and 42 units respectively. It is worth noting that on January 6 th 2004 the MHRA issued a Medical Device Alert for the Aventis Optipen Pro Insulin pen injection system as there was a problem with the plunger as well as dose settings difficulties resulting in insulin administration problems (MDA/2004/002). In excess of 1000 product technical complaints had been received by Aventis by January 2004, after over 130,000 pens had been distributed in the UK. The advice given was to ensure that all patients were adequately trained and proficient in the safe use of the pen. Then On January 11 th 2005 the MHRA issued another medical device alert for the Aventis Optipen Pro insulin pen injection system (MDA/2005/003). There was the potential for the dosage button to fail to engage at the end of an injection, which may lead patients to believe that the injection has not been successful and consider giving another dose. It was advised that patients should be aware of the potential for the dosage button to fail to engage and that if this occurred, they should replace their Optipen with a new one. Use of insulin glargine is reviewed in the October 2004 DTB article, Jan 2005 NEJM paper and March 2005 Prescriber review. Points to highlight include Following subcutaneous injection, insulin glargine forms microprecipitates which gradually redissolve back into solution to enable slow absorption over hours. There is no pronounced peak of action. The injection must be given at the same time each day and can be used with oral antidiabetic drugs in type 2 diabetics. In some people, optimal basal coverage is not obtained with a single injection and a growing minority of users are now taking it twice daily. Variability of absorption remains a problem and erratic glucose control and nocturnal hypoglycaemia, while improved, still trouble some users. Seven randomised controlled trials, involving 2,536 patients with type 1 diabetes and lasting 4-28 weeks have compared once daily insulin glargine with once, twice or four times daily NPH insulin in addition to soluble human insulin or insulin lispro. Only 4 trials assessed HbA1c levels 2 showed a reduction with insulin glargine (0.14% & 0.4%) and 2 showed no change. In terms of hypoglycaemia with insulin glargine, 2 studies reported a significant reduction in symptomatic hypoglycaemia (~10% fewer Not to be used for promotional purposes Page 6 of 13 May be freely copied by NHS agencies
7 patients); 1 study reported a significant reduction in mild hypoglycaemia (~1/3 fewer episodes); 2 studies reported a significant reduction in nocturnal hypoglycaemia (~10-20% fewer patients) and 2 reported no difference in hypoglycaemia. One of the studies did also report more hypoglycaemic episodes with insulin glargine than NPH insulin (p=0.03). Only 3 trials measured weight changes 2 reported no weight gain in either group and one showed reduced weight gain with insulin glargine compared to NPH insulin (0.12kg vs. 0.54kg, p=0.034). In one 28 week trial with 518 type 2 diabetics, changes in HbA1c levels were similar with insulin glargine and NPH insulin as was the frequency of mild symptomatic hypoglycaemic episodes. Nocturnal hypoglycaemia was less likely with insulin glargine (26.5% vs 35.5%, p=0.0136) and there was less weight gain (0.4kg vs. 1.4kg, p<0.0007). A 52 week trial in 426 type 2 diabetics who had not used insulin before found HbA1c levels improved similarly in those on insulin glargine and NPH insulin and weight gain was comparable. Summary Both detemir & galrgine are longer acting analogues given once daily, although detemir is often given twice daily. Both detemir & glargine seem to result in glycaemic control that is at least comparable with NPH insulin. Detemir appears to reduce nocturnal hypoglycaemia & result in less weight gain than NPH insulin in type 1 diabetics. Glargine seems to reduce nocturnal hypoglycaemia in patients with type 1 or 2 diabetes. Impact for Suffolk network NICE recommendations were that glargine is not recommended for routine use in type 2 diabetics who require insulin, but it may be considered in those who Require assistance with injecting insulin Lifestyle is significantly restricted by recurrent symptomatic hypoglycaemia Would otherwise need twice daily basal insulin injections in combination with oral antidiabetic drugs Currently over 250,000 people have been diagnosed with type 1 diabetes in the UK and require life-long insulin. Approximately 1.5 million people have type 2 diabetes, of which it is estimated that about 30% may receive insulin in order to achieve tight glycaemic control. The UK population in 2003 was about 59,600,000. Not to be used for promotional purposes Page 7 of 13 May be freely copied by NHS agencies
8 For full Suffolk details please see Table at end of this section Currently insulin therapy is seen as a last line treatment for type 2 diabetics, however there is a trend to use insulin earlier in type 2 diabetics as a result of information from the UKPDS studies. The UK Prospective Diabetes Study (UKPDS) showed that intensive control of blood glucose, using sulphonylurea or insulin - and, for overweight people, metformin - could reduce the risk of diabetic complications substantially. In addition, the study showed that Type 2 diabetes is characterised by a steady decline in beta cell function that leads to progressive hyperglycaemia despite continued therapy with sulphonylurea or metformin. To offset this, most people with Type 2 diabetes will, in time, need insulin therapy. The RCN produced a publication in 2004 on how to start insulin therapy in adults with type 2 diabetes. s%20with%20type%202%20diabetes.pdf Strong indications for insulin therapy include: symptoms of hyperglycaemia such as polyuria, thirst, recurrent fungal infections (especially genital thrush) or bacterial infections (especially urine infections) pregnancy or planning pregnancy oral hypoglycaemic treatments not tolerated/contra-indicated weight loss without dieting in someone of low or normal weight. Possible indications for insulin therapy include: unsatisfactory glycaemic control, even with the maximum tolerated dose of oral hypoglycaemic agents (HbA1c > 7%, self blood glucose monitoring results > 7 mmols/l before meals or 9 mmols/l 2 hrs after meals) personal preference myocardial infarction - the DIGAMI study (Malmberg et al 1995) suggests that intensive insulin treatment following myocardial infarction improves long-term survival) painful neuropathy foot ulceration and infection. Who may not benefit from insulin treatment? Some obese people - insulin treatment can lead to further weight gain, with little or no improvement in HbA1c. People whose oral hypoglycaemic treatment regimen could be improved - would they prefer to change to a more effective oral Not to be used for promotional purposes Page 8 of 13 May be freely copied by NHS agencies
9 treatment regimen? Elderly people with a short duration of diabetes and no symptoms of hyperglycaemia - are disabling long-term diabetic complications likely to develop in their lifetime? People with other physical or mental health problems - do the potential benefits of insulin treatment outweigh the potential risks, especially the risk of hypoglycaemia? When should insulin treatment be started? Insulin therapy should be discussed as a treatment option at the time of diagnosis. It should not be used as a threatened punishment for poor compliance. Treatment should start: as soon as there is evidence of deteriorating glycaemic control after exploring whether the person could change their lifestyle or current medication after a full discussion of all the pros and cons of insulin therapy. When people don t want insulin therapy Bear in mind that there will be some situations or factors that may put people off starting insulin therapy: occupation - people using insulin cannot hold an LGV or PCV licence, and must undergo a medical assessment before applying for a C1 licence in order to drive vehicles between 3.5 and 7.5 tonnes fear of needles - accurate information can help with this. misconceptions - some people overestimate the risk of hypoglycaemia, while others may be basing their ideas on stories about outdated treatments and equipment live for today - some people may prefer to live with the increased risk of complications, particularly if they do not currently have any symptoms. Costs Insulin analogues Approx. annual cost Short acting Aspart (Novorapid) 360 Lispro (Humalog) 360 Longer acting Detemir (Levemir) 190 Glargine (Lantus) Biphasic Aspart (Novomix 30) Lispro (Humalog Mix25) Conventional human insulin Short acting Actrapid Humulin S Longer acting Humulin I Insultard Biphasic Humulin M3 Mixtard Not to be used for promotional purposes Page 9 of 13 May be freely copied by NHS agencies
10 Prices are taken from MIMS March Costs calculated on cartridge costs, assuming the patient is using 50 units daily of a short acting insulin, 20 units daily of a longer acting insulin or 50 units daily of a biphasic insulin. Economic Information Number of patients in Suffolk with Type 1 and Type 2 Diabetes PCT Type 1 diabetes Type 2 diabetes Central Suffolk 413 1,652 Ipswich 595 2,381 Suffolk Coastal 414 1,657 Waveney 510 2,042 Suffolk West 900 3,600 East system 1,422 5,690 Suffolk total 2,832 11,332 Not to be used for promotional purposes Page 10 of 13 May be freely copied by NHS agencies
11 Charts to be used in the decision making process in Suffolk Quality of Evidence categories Cost utility categories Per life year gained I Strong evidence from at least 1 RCT A Less than 3,000 II-1 Evidence from a well designed CT without randomisation B 3,000 to 20,000 II-2 Evidence from well designed cohort or case controlled study C > 20,000 II-3 Evidence from multiple time series or dramatic results D Negative life years III Opinions of respected clinicians or expert committees IV Evidence inadequate Recommendations informed by cost utility and quality of evidence Key to Table at Right Quality of evidence A B C D ++ Strongly recommended I ++ (high) ++ - X + Recommended II X - Beneficial but high cost III X X Not recommended IV (low) 0 Not proven Adapted from Quick and Clean : authorative health technology assessment for local health care contracting Andrew Stevens, Duncan Collin-Jones & John Gabbay Health Trends Vol 27 No Not to be used for promotional purposes Page 11 of 13 May be freely copied by NHS agencies
12 To Decide If A Medication Is To Be Used In Suffolk Criterion Tends to poor 2 Medium 4 Tends to good Quality of evidence in the papers reviewed IV III II-2 II-1 I Magnitude of effect inferred from the trials reviewed Low Medium High Known Side Effect Profile High Medium Low Known Interactions High Medium Low Concern re Possible Side Effects Not Yet Uncovered High Medium Low Balance of Benefit To Harm (side effects toxicity interactions etc) Poor Medium Good NNT High Medium Low Comparison Of Effectiveness With Other Medicines In Use For Poor Medium Good The Same Condition Severity of Condition to be Treated Trivial Medium Severe Cost Utility Score D C B?A A Recommendations informed by cost utility and quality of evidence 0 X Not to be used for promotional purposes Page 12 of 13 May be freely copied by NHS agencies
13 To Decide Where A Medication Is To Be Used In Suffolk Skills of the prescriber Criterion Red Amber Green D Green Experience Of The Condition Specific Specific Specific General Diagnosis Specific Specific Specific General Monitoring Progress Of Treatment Difficult Specific General General Therapy Patient Selection Difficult Specific Specific Easy Initiation Of Treatment Difficult Difficult Easy Easy Dose Titration Difficult Specific Easy Easy Monitoring Of Side Effects Complex Easy Easy Easy Method Of Administration Complex Normal Normal Normal Discontinuation Of Treatment Complex Complex Easy Easy Green Not to be used for promotional purposes Page 13 of 13 May be freely copied by NHS agencies
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationShort-acting insulins. Biphasic insulins. Intermediate- and long-acting insulins
Recommended Insulin Products This guideline states the Gloucestershire Joint Formulary recommended, first choice insulin products. The intention is to support the choice of treatment for new patients,
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationNew Medicine Report (Adopted by the CCG until review and further
New Medicine Report (Adopted by the CCG until review and further DEXIBUPROFEN notice) Document Status Decision made at Suffolk D&TC 7 th September 2006 Traffic Light Decision Double Green Prescriber s
More informationInsulin Management. By Susan Henry Diabetes Specialist Nurse
Insulin Management By Susan Henry Diabetes Specialist Nurse The Discovery of Insulin - 1921 - Banting & Best University Of Toronto Discovered hormone insulin in pancreatic extract of dog - Marjorie the
More informationWhen and how to start insulin therapy in type 2 diabetes
When and how to start insulin therapy in type 2 diabetes Anne Kilvert MD, FRCP Most patients with type 2 diabetes will eventually require insulin due to the progressive decline in betacell function. Dr
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationTemporary interruption in supply of APIDRA (insulin glulisine) - OPTISET and SOLOSTAR prefilled pens and CLIKSTAR reusable cartridges.
September 2011 Dear Health Care Professional, Temporary interruption in supply of APIDRA (insulin glulisine) - OPTISET and SOLOSTAR prefilled pens and CLIKSTAR reusable cartridges. We would like to inform
More informationThe principles of insulin adjustment guidance
The principles of insulin adjustment guidance Tips for insulin titration Blood glucose (BG) monitoring is needed to help identify the efficacy of treatment in diabetes. Monitor blood glucose according
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Continuous subcutaneous insulin infusion for the treatment of diabetes (review) Final scope Appraisal objective To review
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationPolicy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus Version No. Changes Made Version of July 2018 V0.5 Changes made to the policy following patient engagement including: - the
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationGuide to Starting and Adjusting Insulin for Type 2 Diabetes*
Guide to Starting and Adjusting Insulin for Type 2 Diabetes* www.cadth.ca * Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes, 2008 International Diabetes Center, Minneapolis, MN.
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationNew Medicine Report. Pimecrolimus. RED- Hospital only Date of Last Revision 6 th March 2003
New Medicine Report Document Status Pimecrolimus Reviewed by Suffolk D&T RED- Hospital only Date of Last Revision 6 th March 2003 Approved Name Pimecrolimus Trade Name Elidel Manufacturer Novartis Legal
More informationSHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS
SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS INDICATION Fiasp is indicated for the treatment of diabetes mellitus in adults. Special Note: DMAG has approved
More informationTYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS
TYPE 2 DIABETES CRITERIA FOR REFERRAL TO LEVEL 2 OOHS The aim of the Diabetes level 2 service is to provide a high quality service for safe initiation and optimization of injectable therapy within GP networks.
More informationCase Study: Competitive exercise
Case Study: Competitive exercise 32 year-old cyclist Type 1 diabetes since age 15 Last HbA1 54 No complications and hypo aware On Humalog 8/8/8 and Levemir 15 Complains about significant hypoglycaemia
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationSitagliptin. Agreed by Clinical Priorities Group
New Medicine Report Document Status Sitagliptin Agreed by Clinical Priorities Group Traffic Light Decision Blue- Primary Care Prescriber s Rating Offers an advantage - The product has some value but does
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationInitiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital
Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationINSULIN OVERVIEW. Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro min. 3-5 hrs min.
INSULIN OVERVIEW Type Brand Name Onset Peak Duration Role in glucose management Page Rapid-Acting lispro Humalog 15-30 min 30-90 min 3-5 hrs aspart glulisine Short-Acting Regular insulin NovoLog Apidra
More informationThe York Diabetes Care Model
This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin
More informationNew Medicine Assessment
New Medicine Assessment Insulin Glargine 300 units/ml (Toujeo ) Treatment of type 2 diabetes mellitus in adults Recommendation: Amber 0 Insulin glargine 300 units/ml (Toujeo ) is recommended as an option
More informationDIABETES INDICATIONS FOR INSULIN
DIABETES INDICATIONS FOR INSULIN 1 Introduce the likely need for insulin in the future early on as part of patient education Emphasise that it is the pancreas that fails not the patient Assess if greater
More informationPriorities Advisory Committee
Insulin degludec (Tresiba ) PAC - Insulin degludec (Tresiba ) 2.1 The East of England Priorities Advisory Committee A function of GUIDANCE STATEMENT PAC Recommendations 1. Insulin degludec is NOT recommended
More informationAudit support for continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (review of technology appraisal guidance 57)
Audit support for continuous subcutaneous insulin (review of technology appraisal guidance 57) Issue date: 2008 Audit support Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationExogenous Insulin in type 2 DM
Exogenous Insulin in type 2 DM Russell Scott 2015 Part 1: Some basic biochemistry for Insulin absorption and action MY CHECK LIST Factors influencing insulin action: Forgets to inject Amount given Timing
More informationInsulin Therapy Management. Insulin Therapy
Insulin Therapy Management Insulin Therapy Contents Insulin and its effect on glycemic control Physiology of insulin secretion Insulin pharmacokinetics and regimens Insulin dose adjustment for pregnancy
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More information24 Hour Support. Telephone Available 24 hours a day, 7 days a week
Contents Page What is SHAIRE? 1 What is basal-bolus regimen? 2 Why do I need a basal-bolus regimen? 3 How does basal insulin work? 3 How does rapid-acting insulin work? 4 How often should I test my Blood
More informationClinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures
Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationInsulin analogues Das PP, Datta PG
The ORION Medical Journal 2007 Sep;28:497-500 Insulin analogues Das PP, Datta PG Introduction Diabetes mellitus is a very big challenge for our medical science. To overcome this problem we need newer generation
More informationSCIENTIFIC DISCUSSION
London, 5 October 2005 Product name: NovoMix Procedure No. EMEA/H/C/308/X/18 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationGREEN. Ropinirole Other PD treatments Benzodiazepines Opioids low potency Anticonvulsants Clonidine
New Medicine Report (Adopted by the CCG until review and futher notice) Document Status Traffic Light Decision PRAMIPEXOLE For restless legs syndrome Post Suffolk D&TC GREEN Prescribers Rating Possibly
More informationPre admission & surgery Pre-admission Nurses Association SIG Catherine Prochilo Credentialled Diabetes Nurse Educator Sat 23 March 2013
Pre admission & surgery Pre-admission Nurses Association SIG Catherine Prochilo Credentialled Diabetes Nurse Educator Sat 23 March 2013 www.diabetesvic.org.au Plan/ overview Issue/ presenting problems
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA151 Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus This guidance was issued in
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationInsulin Therapies: An Educational Toolkit
University Hospitals of Leicester, Department of Diabetes and Leicester Diabetes Centre: Insulin Therapies: An Educational Toolkit This document is designed for use by those trained and competent in insulin
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationStarting Insulin in General Practice
Starting Insulin in General Practice Timothy Kenealy GP & Assoc Prof of Integrated Care, University of Auckland Auckland DHB / my version + Counties DHB version Starting Insulin surprisingly simple, safe
More informationInsulin for Adults with Type 2 Diabetes
rth Central London Joint Formulary Committee Insulin for Adults with Type 2 Diabetes Disclaimer This guideline is registered at rth Central London (NCL) Joint Formulary Committee (JFC) and is intended
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationObjectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17
Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationMonitoring in Type 2 Diabetes. Learning Outcomes. Type 2 Diabetes. Senga Hunter Community Diabetes Specialist Nurse
Monitoring in Type 2 Diabetes Senga Hunter Community Diabetes Specialist Nurse Learning Outcomes Understand why blood monitoring is necessary Understand the blood tests for monitoring diabetes Understand
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationLantus levemir conversion
Lantus levemir conversion Search Learn about starting insulin-naïve patients with type 2 diabetes on Levemir. Read Important Safety & Prescribing Info on the HCP Website. Lantus and Levemir have a variety
More informationA review of insulin and insulin regimens in type 2 diabetes
A review of insulin and insulin regimens in type 2 diabetes Joshi S, MBChB, MSc(Pharm) Med, APLS Joshi P*, PhD, FRCP, FRS Med, FICA, MACE Diabetes Care Centre, Louis Pasteur Medical Centre, Pretoria *Emeritus
More informationPremixed Insulin for Type 2 Diabetes. a gu i d e f o r a d u lt s
Premixed Insulin for Type 2 Diabetes a gu i d e f o r a d u lt s March 2009 What This Guide Covers / 2 Type 2 Diabetes / 3 Learning About Blood Sugar / 4 Learning About Insulin / 5 Comparing Medicines
More informationMANAGEMENT OF DIABETES IN PREGNANCY
MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine
More informationUpdate on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy
Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,
More informationSetting The setting was outpatient, secondary care. The economic study was carried out in the UK.
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK Palmer A J, Valentine W J, Ray J A, Foos V, Lurati F, Smith I, Lammert
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationManufacturer Proposed indication. Treatment of type 1 diabetes mellitus (T1DM) in adults who require mealtime insulin to control blood glucose levels
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Prescribing Clinical Network Name, brand
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationNew Medicine Report (Adopted by the CCG until review and further
New Medicine Report (Adopted by the CCG until review and further GRASS ALLERGEN TREATMENT notice) Document Status Decision following Suffolk D&TC meeting Traffic Light Decision Red for 2007 with review
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationPERIOPERATIVE DIABETES GUIDELINE
PERIOPERATIVE DIABETES GUIDELINE This Guideline does not replace the need for the application of clinical judgment in respect to each individual patient. Background Diabetes mellitus is estimated to affect
More informationDIABETES - FACT SHEET
DIABETES - FACT SHEET What is diabetes? Diabetes mellitus, often shortened to diabetes, is a chronic condition that affects the body's ability to control blood sugar level and use energy from food. In
More informationPeer Review Report. [long acting insulin analogues glargine and detemir]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [long acting insulin analogues glargine and detemir] (1) Does the application adequately address the issue of the public
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationInsulin Basic facts. Patient Education Patient Care Services. What is insulin? What types of insulin are there? Basal Insulin
Patient Education Insulin Basic facts Insulin is a protein made by the pancreas that allows your cells to use glucose for energy. There are different types of insulin: Basal long-acting insulin that controls
More informationDiabetes Subcommittee of PTAC meeting held 3 March (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 3 March 2011 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationA Fact Sheet for Parents and Carers Insulin and Diabetes
A Fact Sheet for Parents and Carers Insulin and Diabetes In type 1 diabetes the body stops producing insulin. Insulin therapy is essential in the treatment of type 1 diabetes, together with a healthy eating
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationInsulin Safety. Tracey Roe DSN SSOT partnership trust
Insulin Safety Tracey Roe DSN SSOT partnership trust Insulin Type 1 Type 2 when oral therapies are not tolerated or contra/indicated Post MI Intercurrent illness Pre/peri/post op Gestational diabetes Painful
More information